Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urology | 9 | 2024 | 384 | 2.690 |
Why?
|
Medicare | 23 | 2024 | 6815 | 2.020 |
Why?
|
Prostatic Neoplasms | 18 | 2025 | 11090 | 1.800 |
Why?
|
Urinary Bladder Neoplasms | 7 | 2024 | 2176 | 1.200 |
Why?
|
Cystectomy | 3 | 2024 | 603 | 0.800 |
Why?
|
Motivation | 5 | 2024 | 2018 | 0.780 |
Why?
|
Prospective Payment System | 1 | 2022 | 134 | 0.760 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 130 | 0.650 |
Why?
|
Rural Health Services | 1 | 2023 | 393 | 0.640 |
Why?
|
Hormone Replacement Therapy | 2 | 2015 | 752 | 0.630 |
Why?
|
Hypogonadism | 2 | 2015 | 801 | 0.600 |
Why?
|
Reimbursement Mechanisms | 1 | 2024 | 669 | 0.600 |
Why?
|
Physicians | 4 | 2023 | 4591 | 0.580 |
Why?
|
Urologic Neoplasms | 1 | 2020 | 312 | 0.540 |
Why?
|
Urinary Bladder | 2 | 2022 | 1155 | 0.540 |
Why?
|
Brachytherapy | 1 | 2023 | 1218 | 0.500 |
Why?
|
United States | 24 | 2024 | 72909 | 0.440 |
Why?
|
Testosterone | 2 | 2015 | 2495 | 0.440 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 789 | 0.420 |
Why?
|
Rural Population | 2 | 2023 | 2318 | 0.410 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3834 | 0.390 |
Why?
|
Aged | 30 | 2025 | 171163 | 0.360 |
Why?
|
Reimbursement, Incentive | 3 | 2025 | 541 | 0.360 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2014 | 363 | 0.350 |
Why?
|
Urinary Diversion | 2 | 2020 | 134 | 0.330 |
Why?
|
Medical Oncology | 1 | 2020 | 2339 | 0.310 |
Why?
|
Watchful Waiting | 2 | 2025 | 492 | 0.290 |
Why?
|
Referral and Consultation | 1 | 2020 | 3615 | 0.290 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2559 | 0.270 |
Why?
|
Humans | 49 | 2025 | 765926 | 0.250 |
Why?
|
Male | 33 | 2025 | 363815 | 0.250 |
Why?
|
Telemedicine | 1 | 2023 | 3108 | 0.250 |
Why?
|
Retrospective Studies | 18 | 2024 | 81537 | 0.240 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4044 | 0.230 |
Why?
|
Drug Prescriptions | 3 | 2023 | 1662 | 0.230 |
Why?
|
Urinary Catheterization | 1 | 2024 | 195 | 0.220 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 6542 | 0.210 |
Why?
|
Pain, Postoperative | 3 | 2023 | 1767 | 0.210 |
Why?
|
Neoplasm Invasiveness | 3 | 2020 | 3599 | 0.210 |
Why?
|
Logistic Models | 3 | 2023 | 13273 | 0.200 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2022 | 82 | 0.190 |
Why?
|
Alzheimer Disease | 1 | 2023 | 8722 | 0.190 |
Why?
|
Rural Health | 1 | 2023 | 301 | 0.190 |
Why?
|
Renal Colic | 1 | 2021 | 27 | 0.190 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13631 | 0.180 |
Why?
|
Ureteroscopy | 1 | 2022 | 139 | 0.180 |
Why?
|
Health Expenditures | 3 | 2024 | 2388 | 0.180 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2895 | 0.180 |
Why?
|
Ureteral Calculi | 1 | 2021 | 111 | 0.170 |
Why?
|
Prescriptions | 1 | 2023 | 388 | 0.170 |
Why?
|
Surgical Stomas | 1 | 2020 | 45 | 0.170 |
Why?
|
Hydronephrosis | 1 | 2021 | 274 | 0.170 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59496 | 0.170 |
Why?
|
Hormones | 1 | 2023 | 865 | 0.160 |
Why?
|
Contracture | 1 | 2022 | 235 | 0.160 |
Why?
|
Penile Diseases | 1 | 2019 | 47 | 0.160 |
Why?
|
BCG Vaccine | 2 | 2019 | 380 | 0.150 |
Why?
|
Policy | 1 | 2022 | 512 | 0.150 |
Why?
|
SEER Program | 2 | 2022 | 1443 | 0.150 |
Why?
|
Mycobacterium bovis | 1 | 2019 | 147 | 0.150 |
Why?
|
Financial Management | 1 | 2020 | 161 | 0.150 |
Why?
|
Pennsylvania | 1 | 2019 | 615 | 0.150 |
Why?
|
Health Care Sector | 1 | 2020 | 196 | 0.150 |
Why?
|
Penile Neoplasms | 1 | 2019 | 158 | 0.140 |
Why?
|
Nephrostomy, Percutaneous | 1 | 2018 | 76 | 0.140 |
Why?
|
Career Mobility | 1 | 2020 | 261 | 0.140 |
Why?
|
Alkaline Phosphatase | 1 | 2020 | 855 | 0.130 |
Why?
|
Morphine | 1 | 2020 | 660 | 0.130 |
Why?
|
Urethral Stricture | 1 | 2016 | 50 | 0.130 |
Why?
|
Prostatectomy | 2 | 2022 | 1786 | 0.130 |
Why?
|
Muscle, Smooth | 1 | 2020 | 931 | 0.130 |
Why?
|
Nephrectomy | 1 | 2020 | 927 | 0.120 |
Why?
|
Prostate | 1 | 2023 | 1758 | 0.120 |
Why?
|
Cohort Studies | 5 | 2025 | 41680 | 0.120 |
Why?
|
Urinary Bladder, Overactive | 1 | 2016 | 117 | 0.110 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11196 | 0.110 |
Why?
|
Neoplasms | 1 | 2023 | 22340 | 0.110 |
Why?
|
Urethra | 1 | 2016 | 406 | 0.110 |
Why?
|
Kidney Calculi | 1 | 2018 | 458 | 0.110 |
Why?
|
Drug Utilization | 1 | 2018 | 1187 | 0.100 |
Why?
|
Qualitative Research | 1 | 2023 | 3136 | 0.100 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26282 | 0.090 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 1 | 2011 | 103 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3318 | 0.090 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2011 | 95 | 0.090 |
Why?
|
Preoperative Care | 1 | 2020 | 2248 | 0.090 |
Why?
|
Complementarity Determining Regions | 1 | 2011 | 154 | 0.090 |
Why?
|
Unfolded Protein Response | 1 | 2012 | 239 | 0.090 |
Why?
|
Health Personnel | 1 | 2024 | 3385 | 0.080 |
Why?
|
Patient Discharge | 1 | 2023 | 3460 | 0.080 |
Why?
|
Heat-Shock Proteins | 1 | 2012 | 790 | 0.080 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15645 | 0.080 |
Why?
|
Protein Folding | 1 | 2012 | 868 | 0.080 |
Why?
|
Mental Health | 1 | 2022 | 3272 | 0.070 |
Why?
|
Middle Aged | 11 | 2025 | 223016 | 0.070 |
Why?
|
Sex Factors | 1 | 2020 | 10611 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5509 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5364 | 0.060 |
Why?
|
Administration, Oral | 2 | 2024 | 4016 | 0.060 |
Why?
|
Education, Nursing | 1 | 2024 | 84 | 0.060 |
Why?
|
Michigan | 1 | 2025 | 329 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8346 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10380 | 0.050 |
Why?
|
Female | 9 | 2024 | 396141 | 0.050 |
Why?
|
Morphine Derivatives | 1 | 2022 | 43 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7073 | 0.050 |
Why?
|
Catheters, Indwelling | 1 | 2024 | 436 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3690 | 0.050 |
Why?
|
Private Practice | 1 | 2022 | 154 | 0.050 |
Why?
|
Mitomycin | 1 | 2022 | 261 | 0.050 |
Why?
|
Ownership | 1 | 2023 | 338 | 0.050 |
Why?
|
Incidence | 1 | 2019 | 21513 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8721 | 0.040 |
Why?
|
Androstenes | 1 | 2022 | 177 | 0.040 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 206 | 0.040 |
Why?
|
Hernia, Abdominal | 1 | 2020 | 58 | 0.040 |
Why?
|
Commerce | 1 | 2024 | 612 | 0.040 |
Why?
|
Abdominal Wall | 1 | 2020 | 166 | 0.040 |
Why?
|
Vulnerable Populations | 1 | 2024 | 717 | 0.040 |
Why?
|
Administration, Intravesical | 1 | 2018 | 88 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2022 | 1102 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8037 | 0.040 |
Why?
|
Operating Rooms | 1 | 2024 | 785 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20690 | 0.040 |
Why?
|
Muscles | 1 | 2022 | 1577 | 0.040 |
Why?
|
DNA | 1 | 2011 | 7193 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2018 | 144 | 0.030 |
Why?
|
Nitriles | 1 | 2022 | 981 | 0.030 |
Why?
|
Benzamides | 1 | 2022 | 1376 | 0.030 |
Why?
|
Risk Factors | 1 | 2023 | 74850 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2024 | 3542 | 0.030 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 228 | 0.030 |
Why?
|
Urologic Surgical Procedures | 1 | 2016 | 281 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2018 | 993 | 0.030 |
Why?
|
Adult | 4 | 2021 | 223088 | 0.030 |
Why?
|
Risk Assessment | 1 | 2014 | 24275 | 0.030 |
Why?
|
Publishing | 1 | 2020 | 836 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1916 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcr | 1 | 2011 | 21 | 0.020 |
Why?
|
Prognosis | 2 | 2022 | 29890 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2936 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2012 | 651 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.020 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2012 | 209 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3594 | 0.020 |
Why?
|
Remission Induction | 1 | 2016 | 2413 | 0.020 |
Why?
|
Reoperation | 1 | 2020 | 4308 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 2233 | 0.020 |
Why?
|
Obesity | 2 | 2020 | 13082 | 0.020 |
Why?
|
HeLa Cells | 1 | 2012 | 3070 | 0.020 |
Why?
|
Gene Silencing | 1 | 2012 | 1504 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 9373 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15828 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 13042 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39228 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15802 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54807 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 36547 | 0.010 |
Why?
|
Mice | 2 | 2012 | 81782 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2020 | 65194 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2011 | 11895 | 0.010 |
Why?
|
Animals | 2 | 2012 | 168735 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 59857 | 0.010 |
Why?
|
Signal Transduction | 1 | 2012 | 23597 | 0.000 |
Why?
|
Concepts
(164)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_